Polygenic risk score prediction of multiple sclerosis in individuals of South Asian ancestry
Author:
Breedon Joshua R1ORCID, Marshall Charles R12, Giovannoni Gavin123, van Heel David A3ORCID, Akhtar Shaheen, Anwar Mohammad, Arciero Elena, Asgar Omar, Ashraf Samina, Breen Gerome, Chung Raymond, Curtis Charles J, Chaudhary Shabana, Chowdhury Maharun, Colligan Grainne, Deloukas Panos, Durham Ceri, Durrani Faiza, Eto Fabiola, Finer Sarah, Garcia Ana Angel, Griffiths Chris, Harvey Joanne, Heng Teng, Huang Qin Qin, Hurles Matt, Hunt Karen A, Hussain Shapna, Islam Kamrul, Jacobs Benjamin M, Khan Ahsan, Khan Amara, Lavery Cath, Lee Sang Hyuck, Lerner Robin, MacArthur Daniel, Malawsky Daniel, Martin Hilary, Mason Dan, Mazid Mohammed Bodrul, McDermott John, McSweeney Sanam, Miah Shefa, Munir Sabrina, Newman Bill, Owor Elizabeth, Qureshi Asma, Rahman Samiha, Safa Nishat, Solly John, Tahmasebi Farah, Trembath Richard C, Tricker Karen, Uddin Nasir, Heel David A van, Winckley Caroline, Wright John, Dobson Ruth12, Jacobs Benjamin M12,
Affiliation:
1. Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London , London EC1M 6BQ , UK 2. Department of Neurology, Royal London Hospital , London E1 1FR , UK 3. Blizard Institute, Queen Mary University of London , London E1 2AT , UK
Abstract
AbstractPolygenic risk scores aggregate an individual’s burden of risk alleles to estimate the overall genetic risk for a specific trait or disease. Polygenic risk scores derived from genome-wide association studies of European populations perform poorly for other ancestral groups. Given the potential for future clinical utility, underperformance of polygenic risk scores in South Asian populations has the potential to reinforce health inequalities. To determine whether European-derived polygenic risk scores underperform at multiple sclerosis prediction in a South Asian-ancestry population compared with a European-ancestry cohort, we used data from two longitudinal genetic cohort studies: Genes & Health (2015–present), a study of ∼50 000 British–Bangladeshi and British–Pakistani individuals, and UK Biobank (2006–present), which is comprised of ∼500 000 predominantly White British individuals. We compared individuals with and without multiple sclerosis in both studies (Genes & Health: NCases = 42, NControl = 40 490; UK Biobank: NCases = 2091, NControl = 374 866). Polygenic risk scores were calculated using clumping and thresholding with risk allele effect sizes obtained from the largest multiple sclerosis genome-wide association study to date. Scores were calculated with and without the major histocompatibility complex region, the most influential locus in determining multiple sclerosis risk. Polygenic risk score prediction was evaluated using Nagelkerke’s pseudo-R2 metric adjusted for case ascertainment, age, sex and the first four genetic principal components. We found that, as expected, European-derived polygenic risk scores perform poorly in the Genes & Health cohort, explaining 1.1% (including the major histocompatibility complex) and 1.5% (excluding the major histocompatibility complex) of disease risk. In contrast, multiple sclerosis polygenic risk scores explained 4.8% (including the major histocompatibility complex) and 2.8% (excluding the major histocompatibility complex) of disease risk in European-ancestry UK Biobank participants. These findings suggest that polygenic risk score prediction of multiple sclerosis based on European genome-wide association study results is less accurate in a South Asian population. Genetic studies of ancestrally diverse populations are required to ensure that polygenic risk scores can be useful across ancestries.
Funder
Barts Charity Medical Research Council Clinical Research Training Fellowship UK Multiple Sclerosis Society Genes & Health Wellcome Medical Research Council Higher Education Funding Council for England England Catalyst Health Data Research UK National Health Service National Institute Health Research Clinical Research Network Alnylam Pharmaceuticals, Genomics PLC Life Sciences Industry Consortium of Astra Zeneca PLC Bristol-Myers Squibb Company GlaxoSmithKline Research and Development Limited Maze Therapeutics Inc. Merck Sharp & Dohme LLC Pfizer Inc. Takeda Development Centre Americas Inc
Publisher
Oxford University Press (OUP)
Subject
Neurology,Cellular and Molecular Neuroscience,Biological Psychiatry,Psychiatry and Mental health
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|